文献速递前列腺癌

前列腺癌雄激素受体靶向治疗:抗雄激素药物35年进展

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
PubMed 文献 · J Urol · 2018-05-03

本文综述了抗雄激素药物在前列腺癌治疗中的发展历程与临床获益,通过检索PubMed临床试验,梳理从甾体类到非甾体类再到下一代抗雄激素药物的演变,指出下一代药物在转移性去势抵抗性前列腺癌中显示显著生存获益并获批准,且正在更早期疾病阶段进行测试。

要点

  • 抗雄激素药物化学结构不同,疗效和安全性各异,甾体类因治疗指数不佳被非甾体类取代。
  • 第一代非甾体抗雄激素药物联合去势较单用去势仅有适度临床获益。
  • 下一代无激动活性的抗雄激素药物在转移性去势抵抗性前列腺癌中显示显著生存获益。

核心结论

  • 抗雄激素药物已为前列腺癌治疗提供重要获益,对雄激素受体结构与功能生物学的深入认识将促进更优药物的发现与开发。

研究设计与样本

  • 本文为综述,检索PubMed中抗雄激素药物与前列腺癌相关的临床试验,由多位临床研究者合作撰写。

主要发现

  • 甾体类抗雄激素药物因治疗指数不佳被更安全的非甾体类药物取代。
  • 氟他胺、尼鲁米特和比卡鲁胺主要与去势联合用于联合雄激素阻断,较单用去势仅有适度临床获益。
  • 下一代无激动活性的抗雄激素药物在转移性去势抵抗性前列腺癌随机临床试验中显示显著生存获益,促使恩扎卢胺于2012年8月获批。
  • 阿帕他胺近期已获批,而达罗他胺尚未在美国获批。
  • 下一代抗雄激素药物正在非转移性前列腺癌等更早期疾病状态中积极测试。

关键数值与推荐

  • 恩扎卢胺于2012年8月获批用于转移性去势抵抗性前列腺癌。
  • 阿帕他胺近期已获批,达罗他胺尚未在美国获批。

临床怎么用

  • 临床可依据抗雄激素药物的结构差异、疗效与安全性特征选择药物,下一代药物在转移性去势抵抗性前列腺癌中已显示生存获益。

局限性

  • 本文为历史性综述,未报告系统检索的定量合并结果或样本量等具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate cancer. MATERIALS AND METHODS: We searched PubMed® for clinical trials with the search terms antiandrogens and prostate cancer combined with drug names for antiandrogens. This article represents a collaboration of clinical investigators who have made critical scientific contributions leading to the approval of antiandrogens for treating patients with prostate cancer. RESULTS: Antiandrogens differ in chemical structure and exert varying efficacy and safety profiles. The unfavorable therapeutic index of steroidal antiandrogens led to replacement by safer nonsteroidal agents. Flutamide, nilutamide and bicalutamide, which were designed to target the androgen receptor, were developed primarily for use in combination with castration to provide combined androgen blockade. Modest clinical benefits were observed with the combination of first generation antiandrogens and castration vs castration alone. With increased knowledge of androgen receptor structure and its biological functions a new generation of antiandrogens without agonist activity was designed to provide more potent inhibition of the androgen receptor. Randomized clinical trials in patients with metastatic, castration resistant prostate cancer showed significant survival benefits, which led to the approval of enzalutamide in August 2012. Apalutamide was recently approved while darolutamide is not yet approved in the United States. These next generation antiandrogens are being actively tested in earlier disease states such as nonmetastatic prostate cancer. Evolving knowledge of resistance mechanisms to androgen receptor targeted treatments will stimulate research and drug discovery for additional compounds. Further testing in nonmetastatic castration resistant prostate cancer as well as castration sensitive disease states will hopefully augment our ability to treat a broader spectrum of patients with prostate cancer. CONCLUSIONS: Antiandrogens have already provided important benefits for prostate cancer treatment. Greater knowledge about the structural and functional biology of the androgen receptor in prostate cancer will facilitate further discovery and development of further improved antiandrogens with enhanced clinical activity in patients with advanced metastatic disease. Testing these new agents earlier in the course of prostate cancer may further improve the survival and quality of life of patients with current local and/or systemic treatment modalities.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Crawford ED, Schellhammer PF, McLeod DG, et al. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. J Urol. 2018. PMID: 29730201. doi:10.1016/j.juro.2018.04.083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。